---
title: "Wave Life Sciences Plans To Accelerate Regulatory Engagement With Full Control Of WVE-006"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274519706.md"
datetime: "2026-02-02T13:22:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274519706.md)
  - [en](https://longbridge.com/en/news/274519706.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274519706.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274519706.md) | [繁體中文](https://longbridge.com/zh-HK/news/274519706.md)


# Wave Life Sciences Plans To Accelerate Regulatory Engagement With Full Control Of WVE-006

Feb 2 (Reuters) - WAVE Life Sciences Ltd (WVE.O) :

-   WAVE LIFE SCIENCES ANNOUNCES PLANS TO ACCELERATE REGULATORY ENGAGEMENT WITH FULL CONTROL OF WVE-006 FOR ALPHA-1 ANTITRYPSIN DEFICIENCY
-   WAVE LIFE SCIENCES LTD: PLANS TO ENGAGE FDA ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR WVE-006, WITH REGULATORY FEEDBACK ANTICIPATED MID-2026
-   WAVE LIFE SCIENCES LTD - DATA FROM 400 MG COHORT ON TRACK FOR Q1 2026
-   WAVE LIFE SCIENCES LTD: DATA FROM 600 MG SINGLE AND MULTIDOSE COHORTS ARE EXPECTED IN 2026
-   WAVE LIFE SCIENCES LTD - EXPECTS CASH RUNWAY INTO THIRD QUARTER OF 2028 Source text: Further company coverage: (WVE.O)

### Related Stocks

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Wave Life Sciences Ltd. (WVE.US)](https://longbridge.com/en/quote/WVE.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Virtus LifeSci Biotech Clinical Trls ETF (BBC.US)](https://longbridge.com/en/quote/BBC.US.md)
- [State Street® SPDR® S&P® PhrmctlsETF (XPH.US)](https://longbridge.com/en/quote/XPH.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.](https://longbridge.com/en/news/279115110.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/en/news/278556054.md)
- [AbbVie reports topline data from Phase I ABBV-295 trial](https://longbridge.com/en/news/278540526.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/en/news/279032442.md)
- [CSP International Publishes Disclosure on V2D Création Acquisition](https://longbridge.com/en/news/278778570.md)